Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 70 Years Old) With Partial Onset Seizures

Next Previous
X
Search
Trial Profile

An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 70 Years Old) With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB; UCB Pharma Inc

    • Most Recent Events

    • 17 May 2022 Results of pooled post hoc (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325 studies) analysis published in the Epilepsia
    • 26 Apr 2022 Results of post hoc analysis of 3 phase III trials (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) assessing the time-course of treatment-emergent adverse events (TEAEs) potentially associated with behavioral disorders (BAEs) in adults with focal seizures during adjunctive brivaracetam (BRV) treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 01 Sep 2021 Results of post-hoc analysis of 3 studies (N01252/NCT00490035, N01253/NCT004642 69, N01358/NCT01261325) assessing tolerability and efficacy of brivaracetam (BRV) in patients on 1 or 2 concomitant antiepileptic drugs (AEDs) and in patients on 1 specific concomitant AED, presented at the 34th International Epilepsy Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top